Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage

Phase 0 Terminated 2 enrolled Brigham and Women's Hospital Dr. Jeffrey Thomas Stroke Shield Foundation · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The investigators will test the central hypothesis that DFO treatment after SAH may improve cerebrovascular regulation, mitigate ischemic neural injury, and serve as an effective neuroprotectant against delayed ischemic injury after SAH.

Timeline

Start: 2014-09
Primary completion: 2015-06
Completion: 2015-07

Outcome

Outcome not reported

Stopped: “Principle Investigator is moving to another institution and plans to restart this proctocol in the new location.”

Publications

Van der Loo LE, Aquarius R, Teernstra O, Klijn K, Menovsky T, van Dijk JMC, Bartels R, Boogaarts HD. Iron chelators for acute stroke. Cochrane Database Syst Rev. 2020 Nov 24;11(11):CD009280. doi: 10.1002/14651858.CD009280.pub3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Deferoxamine	Other / unclassified	20 mg/kg	Intravenous